Literature DB >> 22364316

Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.

Iria Castiñeiras, Luisa Fernández-Diaz, Yolanda Juárez, Mercedes Lueiro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22364316     DOI： 10.1111/j.1346-8138.2011.01499.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  3 in total

Review 1.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases.

Authors:  Rosita Saraceno; Marina Talamonti; Marco Galluzzo; Andrea Chiricozzi; Antonio Costanzo; Sergio Chimenti
Journal:  Case Rep Dermatol       Date:  2013-09-26

3.  Erythrodermic psoriasis: pathophysiology and current treatment perspectives.

Authors:  Rasnik K Singh; Kristina M Lee; Derya Ucmak; Merrick Brodsky; Zaza Atanelov; Benjamin Farahnik; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Wilson Liao
Journal:  Psoriasis (Auckl)       Date:  2016-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.